Rema Ramakrishnan1,2, Aiden Doherty3,4,5, Karl Smith-Byrne6, Kazem Rahimi1,5,7,8, Derrick Bennett5,9, Mark Woodward10,11,12, Rosemary Walmsley3,4, Terence Dwyer1,13. 1. Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, United Kingdom. 2. University of New South Wales, Sydney, Australia. 3. Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, United Kingdom. 4. Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. 5. National Institute of Health Research Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom. 6. International Agency for Research on Cancer, Genetic Epidemiology Group, Lyon, France. 7. Deep Medicine, Oxford Martin School, University of Oxford, United Kingdom. 8. Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom. 9. Clinical Trials Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. 10. The George Institute for Global Health, Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, United Kingdom. 11. The George Institute for Global Health, University of New South Wales, Sydney, Australia. 12. Department of Epidemiology, Johns Hopkins University, Baltimore, United States of America. 13. Murdoch Children's Research Institute, Melbourne, Australia.
Abstract
BACKGROUND: Higher levels of physical activity (PA) are associated with a lower risk of cardiovascular disease (CVD). However, uncertainty exists on whether the inverse relationship between PA and incidence of CVD is greater at the highest levels of PA. Past studies have mostly relied on self-reported evidence from questionnaire-based PA, which is crude and cannot capture all PA undertaken. We investigated the association between accelerometer-measured moderate, vigorous, and total PA and incident CVD. METHODS AND FINDINGS: We obtained accelerometer-measured moderate-intensity and vigorous-intensity physical activities and total volume of PA, over a 7-day period in 2013-2015, for 90,211 participants without prior or concurrent CVD in the UK Biobank cohort. Participants in the lowest category of total PA smoked more, had higher body mass index and C-reactive protein, and were diagnosed with hypertension. PA was associated with 3,617 incident CVD cases during 440,004 person-years of follow-up (median (interquartile range [IQR]): 5.2 (1.2) years) using Cox regression models. We found a linear dose-response relationship for PA, whether measured as moderate-intensity, vigorous-intensity, or as total volume, with risk of incident of CVD. Hazard ratios (HRs) and 95% confidence intervals for increasing quarters of the PA distribution relative to the lowest fourth were for moderate-intensity PA: 0.71 (0.65, 0.77), 0.59 (0.54, 0.65), and 0.46 (0.41, 0.51); for vigorous-intensity PA: 0.70 (0.64, 0.77), 0.54 (0.49,0.59), and 0.41 (0.37,0.46); and for total volume of PA: 0.73 (0.67, 0.79), 0.63 (0.57, 0.69), and 0.47 (0.43, 0.52). We took account of potential confounders but unmeasured confounding remains a possibility, and while removal of early deaths did not affect the estimated HRs, we cannot completely dismiss the likelihood that reverse causality has contributed to the findings. Another possible limitation of this work is the quantification of PA intensity-levels based on methods validated in relatively small studies. CONCLUSIONS: In this study, we found no evidence of a threshold for the inverse association between objectively measured moderate, vigorous, and total PA with CVD. Our findings suggest that PA is not only associated with lower risk for of CVD, but the greatest benefit is seen for those who are active at the highest level.
BACKGROUND: Higher levels of physical activity (PA) are associated with a lower risk of cardiovascular disease (CVD). However, uncertainty exists on whether the inverse relationship between PA and incidence of CVD is greater at the highest levels of PA. Past studies have mostly relied on self-reported evidence from questionnaire-based PA, which is crude and cannot capture all PA undertaken. We investigated the association between accelerometer-measured moderate, vigorous, and total PA and incident CVD. METHODS AND FINDINGS: We obtained accelerometer-measured moderate-intensity and vigorous-intensity physical activities and total volume of PA, over a 7-day period in 2013-2015, for 90,211 participants without prior or concurrent CVD in the UK Biobank cohort. Participants in the lowest category of total PA smoked more, had higher body mass index and C-reactive protein, and were diagnosed with hypertension. PA was associated with 3,617 incident CVD cases during 440,004 person-years of follow-up (median (interquartile range [IQR]): 5.2 (1.2) years) using Cox regression models. We found a linear dose-response relationship for PA, whether measured as moderate-intensity, vigorous-intensity, or as total volume, with risk of incident of CVD. Hazard ratios (HRs) and 95% confidence intervals for increasing quarters of the PA distribution relative to the lowest fourth were for moderate-intensity PA: 0.71 (0.65, 0.77), 0.59 (0.54, 0.65), and 0.46 (0.41, 0.51); for vigorous-intensity PA: 0.70 (0.64, 0.77), 0.54 (0.49,0.59), and 0.41 (0.37,0.46); and for total volume of PA: 0.73 (0.67, 0.79), 0.63 (0.57, 0.69), and 0.47 (0.43, 0.52). We took account of potential confounders but unmeasured confounding remains a possibility, and while removal of early deaths did not affect the estimated HRs, we cannot completely dismiss the likelihood that reverse causality has contributed to the findings. Another possible limitation of this work is the quantification of PA intensity-levels based on methods validated in relatively small studies. CONCLUSIONS: In this study, we found no evidence of a threshold for the inverse association between objectively measured moderate, vigorous, and total PA with CVD. Our findings suggest that PA is not only associated with lower risk for of CVD, but the greatest benefit is seen for those who are active at the highest level.
Authors: Richard P Troiano; David Berrigan; Kevin W Dodd; Louise C Mâsse; Timothy Tilert; Margaret McDowell Journal: Med Sci Sports Exerc Date: 2008-01 Impact factor: 5.411
Authors: Cathie Sudlow; John Gallacher; Naomi Allen; Valerie Beral; Paul Burton; John Danesh; Paul Downey; Paul Elliott; Jane Green; Martin Landray; Bette Liu; Paul Matthews; Giok Ong; Jill Pell; Alan Silman; Alan Young; Tim Sprosen; Tim Peakman; Rory Collins Journal: PLoS Med Date: 2015-03-31 Impact factor: 11.069
Authors: Tom White; Kate Westgate; Stefanie Hollidge; Michelle Venables; Patrick Olivier; Nick Wareham; Soren Brage Journal: Int J Obes (Lond) Date: 2019-04-02 Impact factor: 5.095
Authors: Aiden Doherty; Karl Smith-Byrne; Teresa Ferreira; Michael V Holmes; Chris Holmes; Sara L Pulit; Cecilia M Lindgren Journal: Nat Commun Date: 2018-12-10 Impact factor: 14.919
Authors: Ulf Ekelund; Jakob Tarp; Jostein Steene-Johannessen; Bjørge H Hansen; Barbara Jefferis; Morten W Fagerland; Peter Whincup; Keith M Diaz; Steven P Hooker; Ariel Chernofsky; Martin G Larson; Nicole Spartano; Ramachandran S Vasan; Ing-Mari Dohrn; Maria Hagströmer; Charlotte Edwardson; Thomas Yates; Eric Shiroma; Sigmund A Anderssen; I-Min Lee Journal: BMJ Date: 2019-08-21
Authors: Mika Kivimäki; Archana Singh-Manoux; Jaana Pentti; Séverine Sabia; Solja T Nyberg; Lars Alfredsson; Marcel Goldberg; Anders Knutsson; Markku Koskenvuo; Aki Koskinen; Anne Kouvonen; Maria Nordin; Tuula Oksanen; Timo Strandberg; Sakari B Suominen; Töres Theorell; Jussi Vahtera; Ari Väänänen; Marianna Virtanen; Peter Westerholm; Hugo Westerlund; Marie Zins; Sudha Seshadri; G David Batty; Pyry N Sipilä; Martin J Shipley; Joni V Lindbohm; Jane E Ferrie; Markus Jokela Journal: BMJ Date: 2019-04-17
Authors: Anastasia V Poznyak; Nikolay K Sadykhov; Andrey G Kartuesov; Evgeny E Borisov; Vasily N Sukhorukov; Alexander N Orekhov Journal: Int J Mol Sci Date: 2022-06-22 Impact factor: 6.208
Authors: Wilby Williamson; Adam James Lewandowski; Odaro John Huckstep; Winok Lapidaire; Alexander Ooms; Cheryl Tan; Afifah Mohamed; Maryam Alsharqi; Mariane Bertagnolli; William Woodward; Cameron Dockerill; Annabelle McCourt; Yvonne Kenworthy; Holger Burchert; Aiden Doherty; Julia Newton; Henner Hanssen; John Kennedy Cruickshank; Richard McManus; Jane Holmes; Chen Ji; Sharon Love; Elena Frangou; Colin Everett; Melvyn Hillsdon; Helen Dawes; Charlie Foster; Paul Leeson Journal: EClinicalMedicine Date: 2022-05-13
Authors: Katrina L Schultz; Carl Foster; Kimberley Radtke; Susan Bramwell; Cristina Cortis; Andrea Fusco; John P Porcari Journal: J Funct Morphol Kinesiol Date: 2021-05-28